



03-12-07

18W

PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/551,525-Conf. #6212

Filing Date

September 30, 2005

First Named Inventor

Jeff HIMAWAN

Art Unit

1644

Examiner Name

Not Yet Assigned

Attorney Docket Number

ELI-037US

**ENCLOSURES (Check all that apply)**☐ Fee Transmittal Form☐ Fee Attached☐ Amendment/Reply☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☒ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Reply to Missing Parts/  
Incomplete Application☐ Reply to Missing Parts under  
37 CFR 1.52 or 1.53☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a  
Provisional Application☐ Power of Attorney, Revocation  
Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s) \_\_\_\_\_☐ Landscape Table on CD☐ After Allowance Communication  
to TC☐ Appeal Communication to Board of  
Appeals and Interferences☐ Appeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please  
Identify below):

Return Receipt Postcard

PTO form SB/08

Certificate of Mailing

Copies of Fifteen (15) References

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

LAHIVE &amp; COCKFIELD, LLP

Signature

Printed name

Megan E. Williams

Date

March 9, 2007

Reg. No.

43,270

Express Mail Label No. EV 956473010 US Dated: March 9, 2007



Application No. (if known): 10/551,525

Attorney Docket No.: ELI-037US

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 956473010 US in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on March 9, 2007  
Date

Signature

Megan E. Williams

Typed or printed name of person signing Certificate

43,270  
Registration Number, if applicable

(617) 227-7400  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Return Receipt Postcard  
Transmittal (1 page)  
Information Disclosure Statement (2 pages)  
PTO form SB/08 (27 References) (2 pages)  
Copies of Fifteen (15) References



Express Mail Label No. EV 956473010 US Dated: March 9, 2007

Docket No.: ELI-037US  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Jeff Himawan *et al.*

Application No.: 10/551,525

Confirmation No.: 6212

Filed: September 30, 2005

Art Unit: 1644

For: IMMUNOGENICITY-REDUCED ANTI-CR1  
ANTIBODY AND COMPOSITIONS AND  
METHODS OF TREATMENT BASED  
THEREON

Examiner: Not Yet Assigned

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Applicants submit herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. ELI-037US.

Dated: March 9, 2007

MEW/MBC/mch

Respectfully submitted,

By   
Megan E. Williams  
Registration No.: 43,270  
LAHIVE & COCKFIELD, LLP  
One Post Office Square  
Boston, Massachusetts 02109-2127  
(617) 227-7400  
(617) 742-4214 (Fax)  
Attorney/Agent For Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/551,525-Conf. #6212
				Filing Date	September 30, 2005
				First Named Inventor	Jeff HIMAWAN
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	ELI-037US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1*	US-4,816,397	03-28-1989	Boss et al.	
	A2*	US-4,816,567	03-28-1989	Cabilly et al.	
	A3*	US-5,470,570	11-28-1995	Rackley et al.	
	A4*	US-5,487,890	01-30-1996	Taylor et al.	
	A5*	US-5,565,332	10-15-1996	Hoogenboom et al.	
	A6*	US-5,585,089	12-17-1996	Queen et al.	
	A7*	US-5,648,237	07-15-1997	Carter	
	A8*	US-5,693,762	12-02-1997	Queen et al.	
	A9*	US-5,821,337	10-13-1998	Carter et al.	
	A10*	US-5,879,679	03-09-1999	Taylor et al.	
	A11*	US-20050031625-A1	02-10-2005	Mohamed et al.	
	A12*	US-20060263792-A1	11-23-2006	Mohamed et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	WO-98/52976-A1	11-26-1998	Biovation Limited		
	B2	WO-00/34317-A2	06-15-2000	Biovation Limited		
	B3	WO-01/80883-A1	11-01-2001	Elusys Therapeutics, Inc.		
	B4	WO-02/46208-A2	06-13-2002	Elusys Therapeutics, Inc.		
	B5	WO-03/007971-A1	01-30-2003	University of Virginia Patent Foundation		
	B6	WO-04/087759-A2	10-14-2004	Elusys Therapeutics, Inc.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Ferguson, Polly J. et al., "Antigen-Based Heteropolymers," <i>Arthritis &amp; Rheumatism</i> , Vol. 38(2):190-200 (1995)	
	C2	Hahn, Chang S. et al., "Bispecific Monoclonal Antibodies Mediate Binding of Dengue Virus to Erythrocytes in a Monkey Model of Passive Viremia," <i>The Journal of Immunology</i> , Vol. 166:1057-1065 (2001)	
	C3	Hogg, Nancy et al., "Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1)," <i>Eur. J. Immunol.</i> , Vol. 14:236-243 (1984)	

Examiner Signature	Date Considered
-----------------------	--------------------

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/551,525-Conf. #6212
				Filing Date	September 30, 2005
				First Named Inventor	Jeff HIMAWAN
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	ELI-037US

	C4	Kuhn, Susan E. et al., " <i>Escherichia coli</i> Bound to the Primate Erythrocyte Complement Receptor via Bispecific Monoclonal Antibodies Are Transferred to and Phagocytosed by Human Monocytes in and In Vitro Model," <i>The Journal of Immunology</i> , Vol. 160:5088-5097 (1998)	
	C5	Lindorfer, Margaret A. et al., "A bispecific dsDNAXmonoclonal antibody construct for clearance of anti-dsDNA IgG in systemic lupus erythematosus," <i>Journal of Immunological Methods</i> , Vol. 248:125-138 (2001)	
	C6	Lindorfer, Margaret A. et al., "Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications," <i>Immunological Reviews</i> , Vol. 183:10-24 (2001)	
	C7	Lindorfer, Margaret A. et al., "Targeting of <i>Pseudomonas aeruginosa</i> in the Bloodstream with Bispecific Monoclonal Antibodies," <i>The Journal of Immunology</i> , Vol. 167:2240-2249 (2001)	
	C8	Taylor, Ronald P. et al., "Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: A potential therapeutic treatment," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 88:3305-3309 (1991)	
	C9	European Search Report for Application No. 04775855.2 - 2402, dated November 23, 2006	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--